Login / Register

Username:


Password: [Lost?]



New User? Click here for your FREE subscription



Healthcare Professionals
Healthcare Professionals Healthcare Professionals

Follow Us


NEWS-Line on Twitter NEWS-Line on Facebook NEWS-Line on Google+ NEWS-Line on LinkedIn NEWS-Line on Pinterest


Healthcare Conferences &
Educational Opportunities






July 10 - 12

ASHA Connect 2020

American Speech-Language-Hearing Association

July 10 - 12

19th Annual Primary Care Focus Symposium

Baptist Health South Florida Continuing Medical Education

July 13 - 16

Summer Conference

National Association of State Veterans Homes

July 14 - 17

NADONA's 33rd Annual Conference: NADONA! A Lifesave for White Waters Ahead! Barreling Through the Falls to Excellence!

NADONA

Aug. 4 - 07

Destin CME Conference

Skin, Bones, Hearts & Private Parts

More Events

Adding Immunotherapy After Initial Treatment Can Benefit Metastatic Lung Cancer Patients | NEWS-Line for Healthcare Professionals

Adding Immunotherapy After Initial Treatment Can Benefit Metastatic Lung Cancer Patients


Source:

Treating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they’ve completed locally ablative therapy – meaning all known sites of their cancer were either treated with surgery, radiation, or other definitive treatments – almost tripled the median progression-free survival (PFS) compared to the historical average. Research from the Abramson Cancer Center at the University of Pennsylvania found the average PFS of study participants was 19.1 months, compared to 6.6 months. JAMA Oncology published the findings today.

Lung cancer is, by far, the leading cause of cancer death in America, and NSCLC is the most common type. Chemotherapy is the standard treatment, but recent data have shown that patients with limited metastatic disease may have more options.

“Multiple trials have shown that if we use these definitive treatment techniques on all visible tumor sites, patients can end up with better outcomes than what they would get with chemotherapy alone, so our trial went one step further and added immunotherapy,” said lead author Joshua M. Bauml, MD, an assistant professor of Hematology-Oncology in Penn’s Perelman School of Medicine. The study’s senior author was Corey J. Langer, MD, a professor of Hematology-Oncology at Penn.

For this study, 45 NSCLC patients with four or fewer metastatic sites underwent LAT, then received pembrolizumab. In addition to the significant increase in overall average PFS, the average PFS from the start of pembrolizumab was 18.7 months.

Importantly, the treatment did not lead to any new safety issues or decreases in patient quality of life.

“Our understanding of which metastatic patients may benefit from curative therapies as opposed to palliative therapies is still evolving, but our data show promise that the addition of immunotherapy can bring make a difference,” Bauml said.

Researchers say the approach needs further study and that they are still evaluating the impact of this combination on overall survival. However, they note that this study accrued 45 patients from February 2015 through September 2017, a significant number for a single site and evidence that a larger, multicenter, randomized controlled trial to test this approach is feasible.

This study was supported by a grant from Merck, which manufactures pembrolizumab, though the company had no role in the conceptualization, data collection, or analysis and interpretation. The study was also supported by an Abramson Cancer Center Core Grant (P30CA016520).

Source:Perelman School of Medicine at the University of Pennsylvania

Photo Credit:Penn Medicine






Share This!


Healthcare Jobs






Speech/Language Pathologist

Shield Institute
Flushing, New York

Paramedic

Medical Mobile Corporation
Arlington , VA

Chief Executive Officer

New Horizons of the Treasure Coast, Inc
Fort Pierce, FL

Faculty Positions Fall 2020 Nursing Department - Assistant Professor, Medical Surgical Nursing & Assistant Professor, Pediatric Nursing

Borough of Manhattan Community College/CUNY
Manhattan, New York

Clinical Laboratory Manager

Washington State University
Pullman, WA

Speech Language Pathologist

The ARC of Union County
Union County, New Jersey

More Jobs
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.